Retatrutide Doubles Ozempic Weight Loss in Lilly Phase 3 Trial

Lilly's next obesity drug beats Ozempic head-to-head

Eli Lilly's next obesity drug now has head-to-head data against the best-known name in the category. In a Phase 3 trial called TRANSCEND-T2D-2, the experimental triple-hormone drug retatrutide produced more than twice the weight loss of Novo Nordisk's Ozempic at its highest approved dose in adults with type 2 diabetes.2 After 80 weeks, people on the 9 mg dose lost an average of 44.3 pounds (19.5% of body weight) and people on the 12 mg dose lost 47.4 pounds (20.9%). The Ozempic group lost 20.9 pounds (9.4%).2 Both retatrutide doses also lowered A1C, the standard measure of long-term blood sugar, by 2.2 percentage points from an average starting level of 8.3%. Ozempic lowered it by 1.8 points.10

The study enrolled 1,298 adults whose diabetes was not controlled by metformin, with or without an SGLT2 inhibitor. Patients were randomized 2:2:1 to the two retatrutide doses or Ozempic 2 mg.7 Lilly said retatrutide also did better than Ozempic on non-HDL cholesterol, triglycerides and systolic blood pressure.2 At least one outlet noted that the company has not yet released the numbers behind those cardiovascular claims.9

A single comparison sums up the coverage: Lilly's drug cut weight more than twice as much as the current standard. The more useful questions are what that comparison leaves out, how close the drug is to market, and what it means for a company that already earns most of its money from obesity and diabetes drugs.

What the trial shows, and what it doesn't

The outlets broadly agree on the efficacy numbers, which mostly come from Lilly's own topline release.278 Their emphasis differs. Consumer-facing coverage led with pounds lost and the "next Ozempic" framing.14 Business and trade outlets paid more attention to tolerability. Side effects led 4.8% of patients on the 9 mg dose and 7.9% on the 12 mg dose to stop treatment, compared with 2.7% on Ozempic.7 Diarrhea affected 28.3% and 32.7% of patients on the two retatrutide doses, versus 26.4% on Ozempic. Dysesthesia, an abnormal skin sensation, was also more common with retatrutide.9

The study design matters too. The trial was open-label, so patients and doctors knew which drug each person was taking. Lilly sponsored it and has released only topline results.9 The company says full data will come at a medical meeting and in a peer-reviewed journal.8 The comparison is also narrower than the "next Ozempic" framing suggests. Ozempic is approved for diabetes, while Novo sells the same molecule, semaglutide, for weight loss as Wegovy. Retatrutide was not tested against Wegovy in people with obesity alone.9 People with diabetes typically lose less weight on these drugs than people without it. In separate placebo-controlled trials in non-diabetic adults, retatrutide 12 mg produced 28.3% weight loss over 80 weeks and Wegovy produced 14.9% over 68 weeks. Those trials used different populations and durations, so the numbers can't be compared directly.9

Novo pushed back on the weight-only comparison. A spokesperson said Ozempic should not be judged on weight loss alone and pointed to its benefits for heart, kidney and liver health.76 Novo has a point, because outcomes data takes years to build. Still, retatrutide doubling weight loss in a randomized head-to-head trial is hard to dismiss, and it is the sixth Phase 3 trial in which the drug has delivered strong efficacy.2 Earlier this year, a GlobalData analyst called retatrutide the most effective weight-loss drug yet tested in a large pivotal trial.3

One error in the coverage is worth noting. At least one trade report labeled Ozempic as tirzepatide, which is Lilly's own molecule. Ozempic is semaglutide.39

Lilly is now competing with itself

The most telling comparison may be the one Lilly hasn't finished yet. The company is running a separate Phase 3 trial, TRIUMPH-5, that pits retatrutide against tirzepatide, the drug it sells as Mounjaro and Zepbound.98 Earlier full data from TRIUMPH-2 already showed retatrutide pulling ahead of Lilly's current franchise on deep weight loss. On the 12 mg dose, 34.9% of patients lost at least 25% of their body weight and 52% lost at least 20%. In a tirzepatide trial, 34% of patients lost at least 20%.5 The same dataset suggested retatrutide may lower blood sugar less than tirzepatide. About 40% of patients on the top two retatrutide doses reached A1C levels in the healthy range, compared with up to 55.3% in an earlier tirzepatide trial.5

My read is that Lilly is positioning retatrutide for patients who need the most weight loss, not as a replacement for tirzepatide. That makes commercial sense. Mounjaro and Zepbound are carrying the company, and Lilly has no reason to undercut them early.

The timeline to FDA approval

Lilly has said it is aiming to file retatrutide with U.S. regulators in the first quarter of 2027.10 Other coverage says only that the filing is planned for 2027.6 Based on recent history, the FDA review could be quick. The agency approved Lilly's daily obesity pill, orforglipron, sold as Foundayo, on April 1, 2026, 50 days after Lilly filed. It was the first new molecule cleared under the FDA's national priority voucher program.27 One tracker called it the fastest approval of a new molecular entity since 2002.30 Lilly has also filed orforglipron for type 2 diabetes, and no decision has been announced.30

There's no guarantee retatrutide will get the same treatment. Still, the Foundayo approval shows that regulators are now willing to move obesity drugs through review quickly.

Lilly's obesity sales keep growing

The retatrutide results came out the day before Lilly reported third-quarter earnings, and those earnings explain why investors care so much about its pipeline. Revenue rose 39% to $24.4 billion. Mounjaro brought in $10.7 billion, up 65%, and Zepbound brought in $5.35 billion, up 49%.12 Analysts had expected about $22.61 billion in total revenue and adjusted earnings of $6.26 per share. Lilly reported $7.48.11 Lilly raised its full-year revenue forecast to $91 billion to $92 billion, up from $85 billion to $87 billion. It was the third increase this year.16

The company now depends heavily on one molecule. By one count, Mounjaro and Zepbound accounted for 66% of quarterly revenue and 88% of the year-over-year gain.13 Outside the U.S., Mounjaro sales rose 93%.12 It became the first medicine in China to pass $1 billion in revenue in its first full year.15 CEO David Ricks argued the market still has plenty of room to grow. He said Lilly reaches only about 1 in 10 eligible U.S. patients and about 2 in 100 elsewhere.15

Not every product beat expectations. Foundayo brought in $184 million, below the roughly $229 million analysts had expected.16 Novo launched its oral Wegovy first, in the U.S., Europe and the U.K.3 In separate trials, the Wegovy pill posted 13.6% weight loss and Foundayo posted 11.2%. Foundayo's selling point is that patients don't have to follow fasting rules when taking it.28

Prices are falling while sales climb

Pricing is the less-noticed part of this story. In the U.S., Lilly's sales volume rose 41% while realized prices fell 7%, mainly because of Zepbound.12 Excluding a favorable adjustment to rebate estimates, the U.S. price decline was 10%. Lilly expects pricing to remain a headwind in 2027.15 Outside the U.S., realized prices fell 29%, partly because Mounjaro was added to China's national reimbursement list.12 Some coverage linked the lower U.S. prices to a drug pricing agreement Lilly reached with the Trump administration last year.18

Foundayo's pricing shows the same pattern. Self-pay prices run from $149 to $299 a month, and Lilly cut prices on two doses temporarily through December 31, 2026.25 Medicare patients can pay $50 a month through the GLP-1 Bridge program.25 Lilly said rapid uptake of that program lifted U.S. results.17 Novo's Wegovy pill also starts at $149 a month in self-pay.28

One figure needs care: estimates of how much Lilly beat expectations varied by source. CNBC's LSEG consensus put expected earnings at $6.26 a share,11 while Zacks used $5.38.14 Lilly's quarter also included about $900 million in one-time benefits,12 and around $2 billion for the full year that won't recur.15

Lilly's cancer business is growing too

Obesity drugs aren't Lilly's only growth area. Revenue from its oncology, immunology and neuroscience key products doubled from a year earlier.12 Jaypirca, a blood-cancer drug, grew 59%. Inluriyo, an oral breast-cancer drug, ended the quarter with more than 60% of new U.S. prescriptions in its class of metastatic breast-cancer pills.15 These businesses are much smaller than Mounjaro and Zepbound, but they give Lilly some protection if obesity drug prices keep falling.

The bottom line

The answer to the "next Ozempic" question is probably yes, with a caveat: the drug most at risk from retatrutide may be Lilly's own tirzepatide. Lilly's strategy appears to be to keep falling prices from shrinking revenue by selling far more doses and adding more effective drugs on top. The remaining tests are higher dropout rates from side effects, an open-label trial design, and Novo's argument about proven outcomes. TRIUMPH-5 and the planned 2027 FDA filing will show whether retatrutide becomes a mass-market drug or a premium option for patients who need the most weight loss.